Bioenergetic Failure Drives Functional Exhaustion of Monocytes in Acute-on-Chronic Liver Failure.
Deepanshu Maheshwari, Dhananjay Kumar, Rakesh Kumar Jagdish...
https://pubmed.ncbi.nlm.nih.gov/35747140/Actively Recruiting
Led by Beijing 302 Hospital · Updated on 2024-05-07
150
Participants Needed
1
Research Sites
104 weeks
Total Duration
Researchers are investigating the safety and effectiveness of human umbilical cord mesenchymal stem cell UC-MSC transplantation for treating acute-on-chronic liver failure ACLF. ACLF is a serious condition marked by severe inflammation, organ failure, and high risk of death within 28 days. Current treatments are limited, and liver transplantation faces challenges like donor shortages and high costs. This trial aims to provide scientific evidence on whether UC-MSC therapy can improve outcomes for ACLF patients. The study is a randomized, double-blind, placebo-controlled trial involving 150 patients with ACLF. Participants are divided into groups receiving either UC-MSC infusions or placebo alongside standard medical treatment. The treatment involves three weekly infusions initially, followed by a second stage where some patients receive two additional UC-MSC infusions or placebo. The UC-MSC doses are given through peripheral intravenous infusion at specific weeks during the treatment period. Participants will be monitored through regular visits for up to one year, with assessments including survival rates without transplantation and any side effects from treatment. Researchers will also measure blood tests such as bilirubin, albumin, blood urea nitrogen, and scores that evaluate liver disease severity. These checks occur at multiple time points to track changes and safety throughout and after the treatment period.
CONDITIONS
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
T
Tao Yang, MD
Y
Yanhu Wang, MM
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beijing 302 Hospital
Lead Sponsor
Shulan (Hang Zhou) Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - 3 weeks
Participants receive standard medical treatment for acute-on-chronic liver failure plus either 3 weekly infusions of hUC-MSC or placebo at weeks 0, 1, and 2.
3 infusion visits (in-person) at weeks 0, 1, and 2
Duration - 2 weeks
Surviving participants in the MSC group receive 2 additional weekly infusions of hUC-MSC or placebo at weeks 4 and 5.
2 infusion visits (in-person) at weeks 4 and 5
Duration - Up to 48 weeks after treatment
Participants are monitored for transplantation-free survival and treatment-emergent adverse events with ongoing assessments of liver function and clinical status.
Multiple follow-up visits up to week 53
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Deepanshu Maheshwari, Dhananjay Kumar, Rakesh Kumar Jagdish...
https://pubmed.ncbi.nlm.nih.gov/35747140/Fernando Comunello Schacher, Annelise Martins Pezzi da Silva, Lucia Mariano da Rocha Silla...
https://pubmed.ncbi.nlm.nih.gov/34395335/Yulin He, Xingrong Guo, Tingyu Lan...
https://pubmed.ncbi.nlm.nih.gov/34256837/Yu-Hua Li, Ying Xu, Hua-Mei Wu...
https://pubmed.ncbi.nlm.nih.gov/27687792/Bing-Liang Lin, Jun-Feng Chen, Wei-Hong Qiu...
https://pubmed.ncbi.nlm.nih.gov/28370357/Wen-Xiong Xu, Hong-Liang He, Shun-Wen Pan...
https://pubmed.ncbi.nlm.nih.gov/30863450/Dengna Lin, Hao Chen, Jing Xiong...
https://pubmed.ncbi.nlm.nih.gov/36224178/Hao Yu, Ying Feng, Wenjing Du...
https://pubmed.ncbi.nlm.nih.gov/36461584/Ming Shi, Zheng Zhang, Ruonan Xu...
https://pubmed.ncbi.nlm.nih.gov/23197664/Carlos Gilsanz, Maria-Angeles Aller, Sherezade Fuentes-Julian...
https://pubmed.ncbi.nlm.nih.gov/28501004/Beijing 302 Hospital
Lead Sponsor
Shulan (Hang Zhou) Hospital
Collaborating Sponsor